Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. HIV distribution
3. HIV in Africa
4. HIV particle
5. HIV infection timeline
6. Innate immunity - first response to HIV
7. T cell responses
8. CD4 T cells are susceptible to HIV infection
9. First adaptive immune responses
10. Immune responses during HIV infection
11. Evidence that CD8 T cells control HIV infection
12. Viremia control: normal vs. CD8-depletion
13. Acute HIV infection
14. HIV escape mutations
15. Immune control of HIV
16. HLA types and hazard for disease progression
17. CD8 T cells control HIV infection - summary
18. Antibody response to HIV-2
19. Viral membrane fusion
20. HIV envelope structural changes upon binding
21. Generation of neutralising antibodies
22. Vaccines
23. Antibody vaccines for HIV
24. T cell vaccine control of HIV
25. Protection by CD8 T cell-inducing vaccines
26. HIVA DNA/MVA immunization in mice\macaques
27. HIVA DNA + MVA in humans
28. DNA\MVA stimulated CD4 Th1 responses
29. MVA.HIVA boosts HIV-1-specific CD8 T cells
30. Current T cell vaccines for HIV
31. Phase IIB trials - Merck rAd5 vaccine
32. The problem of HIV variability
33. Illustration of the HIV variability problem
34. Only 1/3 of CTL epitope variants recognized
35. Ways to tackle HIV-1 diversity
36. Conclusions
37. Acknowledgements

Topics Covered

• HIV distribution
• HIV in Africa
• HIV particle
• T-cell responses
• CD4 T-cells susceptible to HIV infection
• CD8 T-cells control HIV infection
• Acute HIV infection
• HIV escape mutations when CTL response focused on dominant epitope
• Immune control of HIV
• Antibody response to HIV-1
• Viral membrane fusion
• 5 broadly neutralizing antibodies
• Antibody vaccines for HIV
• T-cell vaccine control of HIV
• CD8+ T-cell inducing vaccines partly protect against SIV/SHIV challenge
• HIVA DNA/MVA immunization in mice and macaques
• HIVA DNA + MVA in humans
• MVA.HIVA boosts HIV-1-specific CD8 T-cells in HIV+ donors on ART
• Current T-cell vaccines for HIV
• Phase IIB trials
• Merck rAd5 vaccine
• The problem of HIV variability
• Ways to tackle HIV-1 diversity

Links

Series:

• Retroviruses

Categories:

• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases
• Vaccines

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Prof. Andrew McMichael has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.